Gleason	B:C0332326
grade	I:C0332326
grouping	I:C0332326
of	O
prostate	O
cancer	I:C0600139
is	O
of	O
prognostic	O
value	I:C1514474
in	O
Asian	O
men	O
.	O

Gleason	O
grade	I:C0332326
grouping	I:C0332326
of	O
prostate	B:C0600139
cancer	I:C0600139
is	O
of	O
prognostic	O
value	I:C1514474
in	O
Asian	O
men	O
.	O

Gleason	O
grade	I:C0332326
grouping	I:C0332326
of	O
prostate	O
cancer	I:C0600139
is	O
of	O
prognostic	B:C1514474
value	I:C1514474
in	O
Asian	O
men	O
.	O

Gleason	O
grade	I:C0332326
grouping	I:C0332326
of	O
prostate	O
cancer	I:C0600139
is	O
of	O
prognostic	O
value	I:C1514474
in	O
Asian	B:C0078988
men	O
.	O

Gleason	O
grade	I:C0332326
grouping	I:C0332326
of	O
prostate	O
cancer	I:C0600139
is	O
of	O
prognostic	O
value	I:C1514474
in	O
Asian	O
men	B:C0025266
.	O

The	O
International	B:C1708333
Society	I:C1708333
of	I:C1708333
Urological	I:C1708333
Pathology	I:C1708333
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	O
Groups	I:C0332326
(	O
Grade	O
Groups	I:C0332326
)	O
originally	O
described	O
by	O
Epstein	O
and	O
colleagues	O
over	O
Gleason	O
score	I:C3203027
(	O
Gleason	O
score	I:C3203027
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	O
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
International	O
Society	I:C1708333
of	I:C1708333
Urological	I:C1708333
Pathology	I:C1708333
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	B:C0332326
Groups	I:C0332326
(	O
Grade	O
Groups	I:C0332326
)	O
originally	O
described	O
by	O
Epstein	O
and	O
colleagues	O
over	O
Gleason	O
score	I:C3203027
(	O
Gleason	O
score	I:C3203027
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	O
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
International	O
Society	I:C1708333
of	I:C1708333
Urological	I:C1708333
Pathology	I:C1708333
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	O
Groups	I:C0332326
(	O
Grade	B:C0332326
Groups	I:C0332326
)	O
originally	O
described	O
by	O
Epstein	O
and	O
colleagues	O
over	O
Gleason	O
score	I:C3203027
(	O
Gleason	O
score	I:C3203027
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	O
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
International	O
Society	I:C1708333
of	I:C1708333
Urological	I:C1708333
Pathology	I:C1708333
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	O
Groups	I:C0332326
(	O
Grade	O
Groups	I:C0332326
)	O
originally	O
described	O
by	O
Epstein	B:C1547383
and	O
colleagues	O
over	O
Gleason	O
score	I:C3203027
(	O
Gleason	O
score	I:C3203027
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	O
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
International	O
Society	I:C1708333
of	I:C1708333
Urological	I:C1708333
Pathology	I:C1708333
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	O
Groups	I:C0332326
(	O
Grade	O
Groups	I:C0332326
)	O
originally	O
described	O
by	O
Epstein	O
and	O
colleagues	O
over	O
Gleason	B:C3203027
score	I:C3203027
(	O
Gleason	O
score	I:C3203027
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	O
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
International	O
Society	I:C1708333
of	I:C1708333
Urological	I:C1708333
Pathology	I:C1708333
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	O
Groups	I:C0332326
(	O
Grade	O
Groups	I:C0332326
)	O
originally	O
described	O
by	O
Epstein	O
and	O
colleagues	O
over	O
Gleason	O
score	I:C3203027
(	O
Gleason	B:C3203027
score	I:C3203027
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	O
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
International	O
Society	I:C1708333
of	I:C1708333
Urological	I:C1708333
Pathology	I:C1708333
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	O
Groups	I:C0332326
(	O
Grade	O
Groups	I:C0332326
)	O
originally	O
described	O
by	O
Epstein	O
and	O
colleagues	O
over	O
Gleason	O
score	I:C3203027
(	O
Gleason	O
score	I:C3203027
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	B:C0425382
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
majority	O
of	O
studies	B:C2603343
validating	O
this	O
revision	O
have	O
been	O
in	O
Caucasian	O
populations	I:C0043157
.	O

The	O
majority	O
of	O
studies	O
validating	O
this	O
revision	O
have	O
been	O
in	O
Caucasian	B:C0043157
populations	I:C0043157
.	O

We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	B:C0332326
system	I:C0332326
was	O
retrospectively	O
associated	O
with	O
biochemical	O
disease	O
-	O
free	O
survival	O
in	O
a	O
mixed	O
-	I:C0015031
ethnicity	I:C0015031
cohort	O
of	O
Asian	O
men	O
.	O

We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	O
system	I:C0332326
was	O
retrospectively	O
associated	O
with	O
biochemical	O
disease	O
-	O
free	O
survival	O
in	O
a	O
mixed	B:C0015031
-	I:C0015031
ethnicity	I:C0015031
cohort	O
of	O
Asian	O
men	O
.	O

We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	O
system	I:C0332326
was	O
retrospectively	O
associated	O
with	O
biochemical	O
disease	O
-	O
free	O
survival	O
in	O
a	O
mixed	O
-	I:C0015031
ethnicity	I:C0015031
cohort	B:C0599755
of	O
Asian	O
men	O
.	O

We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	O
system	I:C0332326
was	O
retrospectively	O
associated	O
with	O
biochemical	O
disease	O
-	O
free	O
survival	O
in	O
a	O
mixed	O
-	I:C0015031
ethnicity	I:C0015031
cohort	O
of	O
Asian	B:C0078988
men	O
.	O

We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	O
system	I:C0332326
was	O
retrospectively	O
associated	O
with	O
biochemical	O
disease	O
-	O
free	O
survival	O
in	O
a	O
mixed	O
-	I:C0015031
ethnicity	I:C0015031
cohort	O
of	O
Asian	O
men	B:C0025266
.	O

A	O
total	O
of	O
680	O
radical	B:C0194810
prostatectomies	I:C0194810
(	O
radical	O
prostatectomies	I:C0194810
)	O
from	O
2005	O
to	O
2014	O
were	O
included	O
.	O

A	O
total	O
of	O
680	O
radical	O
prostatectomies	I:C0194810
(	O
radical	B:C0194810
prostatectomies	I:C0194810
)	O
from	O
2005	O
to	O
2014	O
were	O
included	O
.	O

Gleason	B:C3203027
score	I:C3203027
from	O
initial	O
biopsy	O
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
Grade	O
Groups	I:C0332326
,	O
defined	O
as	O
:	O
1	O
(	O
Gleason	O
score	I:C3203027
≤	O
6	O
)	O
;	O
2	O
(	O
Gleason	O
score	I:C3203027
3+4=7	O
)	O
;	O
3	O
(	O
Gleason	O
score	I:C3203027
4+3=7	O
)	O
;	O
4	O
(	O
Gleason	O
score	I:C3203027
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
Gleason	O
score	I:C3203027
9	O
-	O
10	O
)	O
.	O

Gleason	O
score	I:C3203027
from	O
initial	O
biopsy	B:C0005558
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
Grade	O
Groups	I:C0332326
,	O
defined	O
as	O
:	O
1	O
(	O
Gleason	O
score	I:C3203027
≤	O
6	O
)	O
;	O
2	O
(	O
Gleason	O
score	I:C3203027
3+4=7	O
)	O
;	O
3	O
(	O
Gleason	O
score	I:C3203027
4+3=7	O
)	O
;	O
4	O
(	O
Gleason	O
score	I:C3203027
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
Gleason	O
score	I:C3203027
9	O
-	O
10	O
)	O
.	O

Gleason	O
score	I:C3203027
from	O
initial	O
biopsy	O
and	O
RP	B:C0194810
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
Grade	O
Groups	I:C0332326
,	O
defined	O
as	O
:	O
1	O
(	O
Gleason	O
score	I:C3203027
≤	O
6	O
)	O
;	O
2	O
(	O
Gleason	O
score	I:C3203027
3+4=7	O
)	O
;	O
3	O
(	O
Gleason	O
score	I:C3203027
4+3=7	O
)	O
;	O
4	O
(	O
Gleason	O
score	I:C3203027
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
Gleason	O
score	I:C3203027
9	O
-	O
10	O
)	O
.	O

Gleason	O
score	I:C3203027
from	O
initial	O
biopsy	O
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
Grade	B:C0332326
Groups	I:C0332326
,	O
defined	O
as	O
:	O
1	O
(	O
Gleason	O
score	I:C3203027
≤	O
6	O
)	O
;	O
2	O
(	O
Gleason	O
score	I:C3203027
3+4=7	O
)	O
;	O
3	O
(	O
Gleason	O
score	I:C3203027
4+3=7	O
)	O
;	O
4	O
(	O
Gleason	O
score	I:C3203027
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
Gleason	O
score	I:C3203027
9	O
-	O
10	O
)	O
.	O

Gleason	O
score	I:C3203027
from	O
initial	O
biopsy	O
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
Grade	O
Groups	I:C0332326
,	O
defined	O
as	O
:	O
1	O
(	O
Gleason	B:C3203027
score	I:C3203027
≤	O
6	O
)	O
;	O
2	O
(	O
Gleason	O
score	I:C3203027
3+4=7	O
)	O
;	O
3	O
(	O
Gleason	O
score	I:C3203027
4+3=7	O
)	O
;	O
4	O
(	O
Gleason	O
score	I:C3203027
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
Gleason	O
score	I:C3203027
9	O
-	O
10	O
)	O
.	O

Gleason	O
score	I:C3203027
from	O
initial	O
biopsy	O
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
Grade	O
Groups	I:C0332326
,	O
defined	O
as	O
:	O
1	O
(	O
Gleason	O
score	I:C3203027
≤	O
6	O
)	O
;	O
2	O
(	O
Gleason	B:C3203027
score	I:C3203027
3+4=7	O
)	O
;	O
3	O
(	O
Gleason	O
score	I:C3203027
4+3=7	O
)	O
;	O
4	O
(	O
Gleason	O
score	I:C3203027
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
Gleason	O
score	I:C3203027
9	O
-	O
10	O
)	O
.	O

Gleason	O
score	I:C3203027
from	O
initial	O
biopsy	O
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
Grade	O
Groups	I:C0332326
,	O
defined	O
as	O
:	O
1	O
(	O
Gleason	O
score	I:C3203027
≤	O
6	O
)	O
;	O
2	O
(	O
Gleason	O
score	I:C3203027
3+4=7	O
)	O
;	O
3	O
(	O
Gleason	B:C3203027
score	I:C3203027
4+3=7	O
)	O
;	O
4	O
(	O
Gleason	O
score	I:C3203027
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
Gleason	O
score	I:C3203027
9	O
-	O
10	O
)	O
.	O

Gleason	O
score	I:C3203027
from	O
initial	O
biopsy	O
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
Grade	O
Groups	I:C0332326
,	O
defined	O
as	O
:	O
1	O
(	O
Gleason	O
score	I:C3203027
≤	O
6	O
)	O
;	O
2	O
(	O
Gleason	O
score	I:C3203027
3+4=7	O
)	O
;	O
3	O
(	O
Gleason	O
score	I:C3203027
4+3=7	O
)	O
;	O
4	O
(	O
Gleason	B:C3203027
score	I:C3203027
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
Gleason	O
score	I:C3203027
9	O
-	O
10	O
)	O
.	O

Gleason	O
score	I:C3203027
from	O
initial	O
biopsy	O
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
Grade	O
Groups	I:C0332326
,	O
defined	O
as	O
:	O
1	O
(	O
Gleason	O
score	I:C3203027
≤	O
6	O
)	O
;	O
2	O
(	O
Gleason	O
score	I:C3203027
3+4=7	O
)	O
;	O
3	O
(	O
Gleason	O
score	I:C3203027
4+3=7	O
)	O
;	O
4	O
(	O
Gleason	O
score	I:C3203027
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
Gleason	B:C3203027
score	I:C3203027
9	O
-	O
10	O
)	O
.	O

Biochemical	B:C2985506
recurrence	I:C2985506
was	O
defined	O
as	O
two	O
consecutive	O
post	O
-	O
RP	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
levels	O
of	O
>0.2	O
ng/	O
mL	O
after	O
post	O
-	O
RP	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
reaching	O
the	O
nadir	O
of	O
<	O
0.1	O
ng/	O
mL	O
.	O

Biochemical	O
recurrence	I:C2985506
was	O
defined	O
as	O
two	O
consecutive	O
post	O
-	O
RP	B:C0194810
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
levels	O
of	O
>0.2	O
ng/	O
mL	O
after	O
post	O
-	O
RP	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
reaching	O
the	O
nadir	O
of	O
<	O
0.1	O
ng/	O
mL	O
.	O

Biochemical	O
recurrence	I:C2985506
was	O
defined	O
as	O
two	O
consecutive	O
post	O
-	O
RP	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
levels	O
of	O
>0.2	O
ng/	O
mL	O
after	O
post	O
-	O
RP	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
reaching	O
the	O
nadir	O
of	O
<	O
0.1	O
ng/	O
mL	O
.	O

Biochemical	O
recurrence	I:C2985506
was	O
defined	O
as	O
two	O
consecutive	O
post	O
-	O
RP	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
levels	O
of	O
>0.2	O
ng/	O
mL	O
after	O
post	O
-	O
RP	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
reaching	O
the	O
nadir	O
of	O
<	O
0.1	O
ng/	O
mL	O
.	O

Biochemical	O
recurrence	I:C2985506
was	O
defined	O
as	O
two	O
consecutive	O
post	O
-	O
RP	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
levels	O
of	O
>0.2	O
ng/	O
mL	O
after	O
post	O
-	O
RP	B:C0194810
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
reaching	O
the	O
nadir	O
of	O
<	O
0.1	O
ng/	O
mL	O
.	O

Biochemical	O
recurrence	I:C2985506
was	O
defined	O
as	O
two	O
consecutive	O
post	O
-	O
RP	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
levels	O
of	O
>0.2	O
ng/	O
mL	O
after	O
post	O
-	O
RP	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
reaching	O
the	O
nadir	O
of	O
<	O
0.1	O
ng/	O
mL	O
.	O

Our	O
data	O
showed	O
that	O
Kaplan	O
-	O
Meier	O
analysis	O
revealed	O
significant	O
differences	O
in	O
biochemical	B:C2985506
recurrence	I:C2985506
within	O
Gleason	O
GG	I:C0332326
based	O
on	O
either	O
biopsy	O
or	O
prostatectomy	O
scoring	O
.	O

Our	O
data	O
showed	O
that	O
Kaplan	O
-	O
Meier	O
analysis	O
revealed	O
significant	O
differences	O
in	O
biochemical	O
recurrence	I:C2985506
within	O
Gleason	B:C0332326
GG	I:C0332326
based	O
on	O
either	O
biopsy	O
or	O
prostatectomy	O
scoring	O
.	O

Our	O
data	O
showed	O
that	O
Kaplan	O
-	O
Meier	O
analysis	O
revealed	O
significant	O
differences	O
in	O
biochemical	O
recurrence	I:C2985506
within	O
Gleason	O
GG	I:C0332326
based	O
on	O
either	O
biopsy	B:C0005558
or	O
prostatectomy	O
scoring	O
.	O

Our	O
data	O
showed	O
that	O
Kaplan	O
-	O
Meier	O
analysis	O
revealed	O
significant	O
differences	O
in	O
biochemical	O
recurrence	I:C2985506
within	O
Gleason	O
GG	I:C0332326
based	O
on	O
either	O
biopsy	O
or	O
prostatectomy	B:C0033573
scoring	O
.	O

Multivariate	O
analysis	O
further	O
confirmed	O
that	O
a	O
higher	O
Grade	B:C0332326
Groups	I:C0332326
was	O
significantly	O
associated	O
with	O
risk	O
of	O
biochemical	O
recurrence	I:C2985506
.	O

Multivariate	O
analysis	O
further	O
confirmed	O
that	O
a	O
higher	O
Grade	O
Groups	I:C0332326
was	O
significantly	O
associated	O
with	O
risk	O
of	O
biochemical	B:C2985506
recurrence	I:C2985506
.	O

This	O
GG	B:C0332326
system	I:C0332326
had	O
a	O
higher	O
prognostic	O
discrimination	O
for	O
both	O
initial	O
biopsy	O
and	O
RP	O
than	O
Gleason	O
score	I:C3203027
.	O

This	O
GG	O
system	I:C0332326
had	O
a	O
higher	O
prognostic	O
discrimination	O
for	O
both	O
initial	O
biopsy	B:C0005558
and	O
RP	O
than	O
Gleason	O
score	I:C3203027
.	O

This	O
GG	O
system	I:C0332326
had	O
a	O
higher	O
prognostic	O
discrimination	O
for	O
both	O
initial	O
biopsy	O
and	O
RP	B:C0194810
than	O
Gleason	O
score	I:C3203027
.	O

This	O
GG	O
system	I:C0332326
had	O
a	O
higher	O
prognostic	O
discrimination	O
for	O
both	O
initial	O
biopsy	O
and	O
RP	O
than	O
Gleason	B:C3203027
score	I:C3203027
.	O

Our	O
study	B:C2603343
validates	O
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	O
system	I:C0332326
in	O
a	O
mixed	O
-	I:C0015031
ethnicity	I:C0015031
population	I:C0015031
of	O
Asian	O
men	O
.	O

Our	O
study	O
validates	B:C1519941
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	O
system	I:C0332326
in	O
a	O
mixed	O
-	I:C0015031
ethnicity	I:C0015031
population	I:C0015031
of	O
Asian	O
men	O
.	O

Our	O
study	O
validates	O
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	B:C0332326
system	I:C0332326
in	O
a	O
mixed	O
-	I:C0015031
ethnicity	I:C0015031
population	I:C0015031
of	O
Asian	O
men	O
.	O

Our	O
study	O
validates	O
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	O
system	I:C0332326
in	O
a	O
mixed	B:C0015031
-	I:C0015031
ethnicity	I:C0015031
population	I:C0015031
of	O
Asian	O
men	O
.	O

Our	O
study	O
validates	O
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	O
system	I:C0332326
in	O
a	O
mixed	O
-	I:C0015031
ethnicity	I:C0015031
population	I:C0015031
of	O
Asian	B:C0078988
men	O
.	O

Our	O
study	O
validates	O
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	O
system	I:C0332326
in	O
a	O
mixed	O
-	I:C0015031
ethnicity	I:C0015031
population	I:C0015031
of	O
Asian	O
men	B:C0025266
.	O

Higher	O
Grade	B:C0332326
Groups	I:C0332326
was	O
significantly	O
associated	O
with	O
increased	O
risk	O
of	O
biochemical	O
recurrence	I:C2985506
.	O

Higher	O
Grade	O
Groups	I:C0332326
was	O
significantly	O
associated	O
with	O
increased	O
risk	O
of	O
biochemical	B:C2985506
recurrence	I:C2985506
.	O

We	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical	B:C1516615
management	I:C1516615
for	O
patients	O
with	O
prostate	O
cancer	I:C0600139
.	O

We	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical	O
management	I:C1516615
for	O
patients	O
with	O
prostate	B:C0600139
cancer	I:C0600139
.	O

